APA (7th ed.) Citation

DH, U., J, L., SM, G., S, V., C, U., BS, R., . . . DS, Z. (2025). High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic. Neuro-oncology, 27(7), 1813. https://doi.org/10.1093/neuonc/noaf035

Chicago Style (17th ed.) Citation

DH, Upton, et al. "High-throughput in Vitro Drug Screening and in Vivo Studies Identify Fenretinide as a Brain-penetrant DMG Therapeutic." Neuro-oncology 27, no. 7 (2025): 1813. https://doi.org/10.1093/neuonc/noaf035.

MLA (9th ed.) Citation

DH, Upton, et al. "High-throughput in Vitro Drug Screening and in Vivo Studies Identify Fenretinide as a Brain-penetrant DMG Therapeutic." Neuro-oncology, vol. 27, no. 7, 2025, p. 1813, https://doi.org/10.1093/neuonc/noaf035.